Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AT-527 (bemnifosbuvir) an oral nucleotide polymerase inhibitor, small molecule drug candidate, which is being evaluated for the treatment of Covid-19 infection.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
AT-527 (bemnifosbuvir) targets the SARS-CoV-2 RNA polymerase (nsp12), a highly conserved gene which is responsible for both replication and transcription of SARS-CoV-2. It is under phase 3 clinical trials for the treatment of COVID-19 Infection.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
AT-527 (bemnifosbuvir) is a nucleotide polymerase inhibitor, targets the SARS-CoV-2 RNA polymerase (nsp12), a highly conserved gene that is unlikely to change as the virus mutates and vRuzasvir (RZR), an oral NS5A inhibitor for Treatment of Hepatitis C.
Lead Product(s): Bemnifosbuvir,Ruzasvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
AT-527 (bemnifosbuvir) is a nucleotide polymerase inhibitor, targets the SARS-CoV-2 RNA polymerase (nsp12), a highly conserved gene that is unlikely to change as the virus mutates and variants continue to emerge.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
AT-527 (bemnifosbuvir) is designed to inhibit viral replication by impairing viral RNA polymerase, a key component in the replication machinery of enveloped positive single-stranded RNA viruses, such as human coronaviruses and human flaviviruses.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2023
Details:
Under the terms of the agreement, Atea will develop, manufacture and commercialize AT-038 (ruzasvir), an oral NS5A inhibitor, in combination with AT-527 (bemnifosbuvir) as a pan-genotypic regimen for the treatment of hepatitis C (HCV).
Lead Product(s): Ruzasvir,Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-038
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 07, 2023
Details:
AT-527 (bemnifosbuvir) is an oral direct-acting antiviral which is being studied to determine its potential to protect against disease progression, and the development of long-COVID complications.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
AT-752 is a novel, orally administered, direct-acting antiviral in Phase 2 development with a Fast Track designation from the U.S. Food and Drug Administration for treatment of dengue.
Lead Product(s): AT-752
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-752
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Bemnifosbuvir (AT-527) targets SARS-CoV-2 RNA polymerase (nsp12), a highly conserved gene that is unlikely to change as the virus mutates and new variants continue to emerge.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
Bemnifosbuvir demonstrated favorable overall nonclinical safety profile, including lack of reproductive and development toxicity in animal models, there were no AT-527-related effects on the fertility, reproduction, embryofetal and postnatal development in rats.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022